All News

This is Measles If You've Never Seen It
February 25, 2025

Here, the 5 key signs and symptoms that characterize measles in the order of appearance.

Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial
February 25, 2025

Symbravo, compared with previous CGRP inhibitor therapy, achieved superior response across efficacy measures including pain freedom and improvements in QoL.

Obesity and Mental Health: Expert Details Interplay, How the Sexes Differ
February 24, 2025

Shagun Bindlish, MD, discusses the complex interplay between obesity and mental health conditions and how sex is a potential moderating factor.

Arcutis Announces Positive Phase 3 Data on Roflumilast Cream 0.05% for Atopic Dermatitis in Young Children
February 24, 2025

Investigators reported that roflumilast cream 0.05% significantly reduced AD severity as early as Week 1, with a notable effect on pruritus seen in as little as 24 hours.

FDA Authorizes Aptitude Metrix COVID/Flu Multiplex Molecular Test for Home and Point-of-Care Use
February 24, 2025

The Metrix COVID/Flu molecular test detects and differentiates SARS-CoV-2, influenza A, and influenza B in approximately 20 minutes.

FDA Approves Expanded Use for Sublocade for Opioid Use Disorder
February 24, 2025

These label changes to Sublocade from Indivior mark a significant advancement in the management of moderate to severe opioid use disorder.

Sinaptica Announces Enrollment for Phase 2 Clinical Trial in Early Alzheimer Disease of Dual Neuromodulation System
February 24, 2025

The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.

Depression Increases Risk For and Accrual of Long-Term Health Disorders
February 21, 2025

Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.

Dupilumab Cardiometabolic Safety in Real-World Study of Atopic Dermatitis Supports Clinical Trial Evidence
February 21, 2025

Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.

Cancer Rates in Black Individuals Decline but Still Outpace Other Racial, Ethnic Groups, Says American Cancer Society
February 21, 2025

The outsized burden continues among Black men, a group with prostate cancer incidence rates 67% higher than those of White men and mortality rates more than twice as high.